NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.

NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas. J Clin Oncol. 2021 03 01; 39(7):797-806.

View in: PubMed

subject areas

Adolescent
Adult
Benzamides
Diphenylamine
Female
Humans
Magnetic Resonance Imaging
Male
Mitogen-Activated Protein Kinase Kinases
Neurofibroma, Plexiform
Neurofibromatosis 1
Protein Kinase Inhibitors
Time Factors
Treatment Outcome
United States
Young Adult

authors with profiles

James Howard Tonsgard